Company Overview of Cordex Pharma, Inc.
Cordex Pharma, Inc., through its subsidiary, Duska Scientific Co., develops cardiovascular medicines based upon the pharmacology of adenosine 5-triphosphate (ATP) and nitric oxide (NO). The company's product portfolio includes ATPace, which is used to treat paroxysmal supraventricular tachycardia; CDP-1050, a once-a-day tablet formulation to restore the redox-NO balance in patients with chronic heart failure; and Vagonixen, a drug to treat chronic obstructive pulmonary disease and chronic cough. Its products also comprise ATPotent, a drug for the treatment of sperm of infertile males in conjunction with in vitro fertilization and intra-uterine insemination procedure; and Ocuprene, a drug for...
470 Nautilus Street
La Jolla, CA 92037
Key Executives for Cordex Pharma, Inc.
Medical Director of Duska Scientific Co
Compensation as of Fiscal Year 2014.
Cordex Pharma, Inc. Key Developments
SEC Orders Hearings On Registration Suspension Or Revocation Against Cordex Pharma, Inc. For Failure To Make Required Periodic Filings
Jun 18 14
Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Cordex Pharma, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries